Find drugs by alphabetical list:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z View All
ImClone Ex-Chief Embarks on New Biotech Venture - New York Times
New York TimesImClone Ex-Chief Embarks on New Biotech VentureNew York TimesMr. Waksal led ImClone as it developed the cancer drug Erbitux, which was approved in 2004, after he had gone to prison. In 2008, Eli Lilly & Company ...and more��
New Insights on Who Should Take Erbitux for Colon Cancer - BusinessWeek
MD News (press release)New Insights on Who Should Take Erbitux for Colon CancerBusinessWeek... not receive the targeted therapy cetuximab (Erbitux), a new study finds that a subset of these patients might actually benefit from taking the drug. ...Lilly's Erbitux May Help Some Cancer Patients With Mutation, Study FindsBloombergSpecific KRAS Mutation Responds to CetuximabMedPage TodayHorizon Discovery's X-MAN cell-models predict that a subset of KRAS mutated ...Cambridge NetworkHemOncTodayall 29 news articles��
AZ sues Watson to stop copycat Crestor; Erbitux study raises KRAS questions; - FiercePharma
AZ sues Watson to stop copycat Crestor; Erbitux study raises KRAS questions;FiercePharmaReport > Eli Lilly and Merck KGaA's Erbitux helped a group of cancer patients thought to be immune to the treatment in a study that contradicts earlier ...and more��
Erbitux may help fight breast cancer, claims study - Reuters
Erbitux may help fight breast cancer, claims studyReutersAdding Erbitux to cisplatin, a platinum-based chemotherapy, doubled the tumor response rate and the length of time patients lived without their disease ...Merck KGaA's Erbitux Delays Progression of Breast Cancer in TestBloombergResults of a Randomized Phase II Study with Erbitux in Breast Cancer ...National Post (registration)Early Tumor Shrinkage with 1st Line Erbitux Therapy Leads to Longest-Ever ...National Post (registration)pharmabiz.com�-Trading Markets (press release)�-ThirdAgeall 52 news articles��
Last updated on: Jan 24, 2007
Brand Name: | Erbitux |
Active Ingredient: | Cetuximab |
Strength(s): | 100mg/50 mL vial |
Dosage Form(s): | Injection |
Company Name: | ImClone Systems Inc.; Bristol-Myers Squibb Co. |
Availability: | Prescription only |
*Date Approved by FDA: | February 12, 2004 |
*Approval by FDA does not mean that the drug is available for consumers at this time.
This information is provided by the U.S. Food & Drug Administration.
For more information about this drug, click here. |
What is Erbitux used for?
Erbitux is a chemotherapy medicine (medicine used to kill cancer cells) that is given in a vein (I.V. infusion). It is used to treat a type of cancer of the colon or rectum that has spread to other areas of the body (EGRF-expressing metastatic colorectal carcinoma). Erbitux is used:
with another chemotherapy medicine called irinotecan in people whose EGFR-expressing metastatic colorectal cancer is not or no longer shrinking with irinotecan alone
alone in people with EGFR-expressing metastatic colorectal cancer who cannot take irinotecan
At this time, it is not known whether Erbitux will improve symptoms of EGFR- expressing colorectal cancer or help these patients to live longer.
Special Warnings with Erbitux:
Erbitux may cause severe reactions during I.V. infusion that may result in death. The reactions include symptoms that happen suddenly such as trouble breathing, an itchy swelling on the skin (hives), and low blood pressure. These severe reactions can happen with any Erbitux infusion, but have happened more often the first time Erbitux is given. People that have severe infusion reactions with Erbitux must have their infusion stopped right away, and cannot be treated with Erbitux again.
Erbitux may cause a serious lung condition called interstitial lung disease that results in inflammation, scarring, and hardening of the lungs.
Erbitux often causes skin reactions such as an acne-like rash, drying, cracking, inflammation, and infections. These reactions may be worsened by sun exposure.
General Precautions with Erbitux:
Wear sunscreen, hats, and protective clothing, and limit sun exposure during treatment with Erbitux.
Women who can become pregnant should avoid pregnancy and use contraception during treatment with Erbitux.
Women should not breastfeed during treatment with Erbitux and for 60 days after the last dose.
What should I tell my health care provider?
Tell your health care provider if you are allergic to any of the ingredients of Erbitux.
What are some possible side effects of Erbitux? (This list is NOT a complete list of side effects reported with Erbitux. Your health care provider can discuss with you a more complete list of side effects.)
Serious side effects of Erbitux include:
The most common side effects of Erbitux include:
Accupril
Actonel
Actos
Allegra
Altace
Atenolol
Avandia
Celebrex
Celexa
Cialis
Coreg
Cozaar
Crestor
Diovan
Effexor
Evista
Flomax
Fluoxetine
Fosamax
Glucophage
Latisse
Levitra
Levoxyl
Lexapro
Lipitor
Lisinopril
Metformin
Neurontin
Nexium
Norvasc
Paxil
Plavix
Pravachol
Premarin
Prevacid
Prilosec
Propecia
Protonix
Prozac
Seroquel
Simvastatin
Singulair
Toprol-XL
Viagra
Zetia
Zithromax
Zocor
Zoloft
Zyprexa
Zyrtec
Loading